Bagsværd, Denmark, 4 November 2020 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
In line with the Principles for remuneration of executives in Novo Nordisk A/S (Remuneration Principles) the Board of Directors may when recruiting new executives who are not employed by Novo Nordisk at the time of employment provide a recruitment package in the form of cash payment or share incentive programme.
The reporting below reflects shares granted to Mr. Ludovic Helfgott in relation to his employment as executive in 2019.
See the full announcement in attached pdf.
Mette Kruse Danielsen
+45 4442 3883
Ken Inchausti (US)
+1 609 240 9429
Daniel Muusmann Bohsen
+45 3075 2175
Valdemar Borum Svarrer
+45 3079 0301
Ann Søndermølle Rendbæk
+45 3075 2253
Mark Joseph Root
+45 3079 4211
Kristoffer Due Berg US)
+1 609 235 2989
Company announcement No 67 / 2020